Product Code: RP-ID-10094818 |
Published Date: 21 Mar 2025 |
Region: Global |
Category: Healthcare & Pharmaceuticals |
Report ID: 10094818
Market Overview:
Chemotherapy Market Segmentation by Cancer Type (Lung, Breast, Stomach, and Ovarian Cancer, and Others); by Gender Type (Male, and Female); and by Product Type (Pump, Cannula, Catheter, and Others)-Global Demand Analysis & Opportunity Outlook 2022-2031
Global Chemotherapy Market Highlights Over 2022 - 2031
The global chemotherapy market is estimated to grow at a notable CAGR over the forecast period, i.e., 2022–2031. Moreover, in the year 2021, the market registered a remarkable revenue. The growth of the market can be attributed to the rising cancer cases and the increasing population. For instance, according to a report by the World Health Organisation, worldwide, the second leading reason for mortality is cancer that, accounted for approximately 9.6 million deaths in 2018. Additionally, the increase in expenditure on medicine and research and development are some of the major factors expected to boost the growth of the global chemotherapy market.
GET A SAMPLE COPY OF THIS REPORT
The global chemotherapy market is segmented by cancer type into the lung, stomach, ovarian, breast cancer, and others. Among these segments, the breast cancer segment in the global chemotherapy market is estimated to witness the highest growth over the forecast period. The growth of the segment can be attributed to the increasing awareness among people related to breast cancer. According to the World Cancer Research Fund, 2,261,419 new breast cases were reported in the year 2020, which constitutes the highest number in relation to other cancer types. Therefore, rising breast cancer cases are expected to increase the growth of the global chemotherapy market.
Global Chemotherapy Market Regional Synopsis
Regionally, the global chemotherapy market is segmented into five major regions, including North America, Europe, Asia Pacific, Latin America, and Middle East & Africa region. The Asia Pacific region in the global chemotherapy market is estimated to witness modest growth over the forecast period on the back of a rising population in the particular region. According to the World Bank, China and India are among the countries with the largest populations, having 1,411.0 and 1,380.0 million populations respectively, in 2020, and their numbers are increasing on a yearly basis. Additionally, the rising cancer awareness among the population and increasing expenditure on research related to cancer in this region is further expected to boost market growth.
Market Segmentation
Our in-depth analysis of the global chemotherapy market includes the following segments:
By Cancer Type
-
Lung Cancer
-
Breast Cancer
-
Stomach Cancer
-
Ovarian Cancer
-
Others
By Gender Type
-
Male
-
Female
By Product Type
-
Pump
-
Cannula
-
Catheter
-
Others
Growth Drivers and Challenges Impacting the Growth of the Global Chemotherapy Market
Growth Drivers
-
Increasing population
-
Increase in the expenditure on medicine and research
-
Increase in the awareness related to cancer
Challenges
-
High cost of the treatment
-
Lack of government support related to cancer treatments in the countries
Key Companies Dominating the Global Chemotherapy Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global chemotherapy market that are included in our report are Amgen Inc., Pfizer Inc., ALMATICA PHARMA LLC., Bayer AG, Puma Biotechnology, Inc., Sanofi, Astellas Pharma Inc., CLOVIS ONCOLOGY, Novartis AG, BeiGene, Ltd., and others.
Latest Developments in the Global Chemotherapy Market:
6 January 2022: As a second or third line treatment, Tislelizumab manufactured by BeiGene, Ltd., has been approved by the China National Medical Products Administration(NMPA) for patients suffering from locally advanced or metastatic non-small cell lung cancer.
14 January 2021: FDA approves Pfizer’s XALKORI for use in children and young adults in case of the ALK-positive anaplastic large cell lymphoma.
Key Reasons to Buy Our Report
-
The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis and challenges that impact the market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
-
We provide customized reports as per the clients’ requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.
- Amgen Inc.
- Pfizer Inc.
- ALMATICA PHARMA LLC.
- Bayer AG
- Puma Biotechnology, Inc.
- Sanofi
- Astellas Pharma Inc.
- CLOVIS ONCOLOGY
- Novartis AG
- BeiGene, Ltd.
Related Reports
Proof of Quality & Reliability
